Please assess the completion status of the following clinical trial:

Trial Title: ThromboAblation in Acute Myocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Electrocardiographic inclusion criteria: (baseline 12-lead ECG recorded at 25 mm/second upon arrival at investigational center)~* STEMI within 12 hours of symptom onset, with ≥ 2 mm ST segment elevation in two or more leads and minimum ≥ 3 mm ST segment elevation in one lead.~Angiographic inclusion criteria after crossing with guidewire:~* IRA is a native coronary artery; and,~* Reference vessel diameter 2.5 - 4.0 mm; and,~* TIMI 0 or 1 flow with any TIMI thrombus grade; or,~* TIMI 2 or 3 flow with TIMI thrombus grade 3 or greater~Exclusion Criteria:~* Patient unwilling or unable to give informed consent~* Previous MI in the distribution of the current IRA~* Previous CABG~* Contraindications to PCI~  * allergy(s) to intended study medications~ * contraindicated for stent implantation~* Active bleeding or coagulopathy~* Patient in cardiogenic shock (\<90mmHg SBP and/or requiring IABP or vasopressors)~* Known left ventricular ejection fraction (EF) \<30%~* Fibrinolytic administered before PCI~* Renal insufficiency (creatinine \>2.0mg/dl)~* Current vitamin K antagonist therapy or known INR \>1.5~* Known thrombocytopenia - platelets \<100,000 cell count~* Patient has Left Bundle Branch Block (LBBB) or pacemaker rhythm~* Known history of hemorrhagic stroke (CVA or TIA) \<2 years before screening~* Known or suspected pregnancy~* Current cancer disease~* Comorbidity where survival is anticipated to be \<1 year.~* No future patient cooperation expected~* Patient is participating in another clinical study~* Patient \<18 years of age

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ELCA (Type: ACTIVE_COMPARATOR): Laser Thromboablation
- PTCA (Type: ACTIVE_COMPARATOR): PTCA (Direct Stenting)

Based on this trial design, predict the completion outcome and termination type (if applicable).